

	Trading – Interest Rate Derivatives	\boxtimes	Back-office - Options
\boxtimes	Trading – Equity and Index Derivatives	\boxtimes	Technology
	Back-office – Futures	\boxtimes	Regulation
			MCeX

CIRCULAR November 9, 2010

ANTICIPATED CONTRACT ADJUSTMENT

Valeant Pharmaceuticals International, Inc. (VRX)

Special cash dividend

THE FOLLOWING INFORMATION IS PREPARED FOR THE CONVENIENCE OF <u>CANADIAN DERIVATIVES CLEARING CORPORATION (CDCC) MEMBERS AND BOURSE DE MONTRÉAL INC. (THE BOURSE) APPROVED PARTICIPANTS.</u> THIS DOCUMENT IS AN UNOFFICIAL SUMMARY OF CERTAIN TERMS OF THE AFOREMENTIONED ADJUSTMENT. CDCC AND THE BOURSE ACCEPT NO RESPONSIBILITY FOR THE ACCURACY OR COMPLETENESS OF THE SUMMARY. CDCC MEMBERS AND BOURSE APPROVED PARTICIPANTS MUST ENSURE THEY HAVE REVIEWED THE DOCUMENTATION PUBLISHED BY THE ISSUERS INVOLVED IN THIS CORPORATE ACTION.

The Bourse and CDCC wish to inform you that Valeant Pharmaceuticals International, Inc. (the "Company") announced on November 4, 2010, that the Company's Board of Directors has declared a one-time special dividend of US\$1.00 per common share (the "Special Dividend") that shareholders of record as of the close of business on November 15, 2010 will be entitled to receive on December 22, 2010.

The Special Dividend is connected with the accomplishment on September 28, 2010 of the previously announced merger of Valeant Pharmaceuticals International, Inc. and Biovail Corporation.

PLEASE ENSURE THAT ALL CLIENTS WHO HAVE EITHER LONG OR SHORT POSITIONS IN THIS OPTION CLASS ARE ADVISED OF THIS NOTICE.

For further information, please contact Louise Leclair, Trading Systems Analyst Market Operations, Bourse de Montréal Inc. at (514) 871-3526. Clearing members may contact the CDCC Member Services Department.

Brian Gelfand

Vice-President, Institutional Relations and Market Operations

Circulaire no: 149-2010